Eli Lilly and Company
For nearly 150 years, we’ve made significant and game-changing progress on our mission to make life better for people around the world. We’ve remained headquartered in Indianapolis, Indiana, since our founding on May 10, 1876, but our employees now work in countries around the world.
And thanks to the dedication of our diverse global team, we’ve been able to answer the call for new medicines to help solve some of the world’s most significant health challenges
When you’re on a mission to do what’s never been done before, you seek people willing to challenge the status quo of medicine. Those willing to relentlessly pursue what’s next, all in the name of health above all. #WeAreLilly
We are Lilly
Why do our employees love coming to work each and every day? Here’s what they have to say.
47,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know Team Lilly through our Powered by Purpose series.
NEWS
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 2, 2021.
It was a busy week for clinical trial news. Read on for more information.
Today marked some wheeling and dealing in the life sciences industry as several companies licensed products or invested in other companies. Here’s a look.
Vir Biotechnology, Eli Lilly and GlaxoSmithKline struck a three-way collaborative deal to evaluate its investigational monoclonal antibody, VIR-7831, in combination with Lilly’s bamlanivimab in low-risk patients with mild to moderate COVID-19.
New Phase III efficacy data from Eli Lilly showed that a combination of two experimental neutralizing antibodies, bamlanivimab and etesevimab, met the primary endpoint of reduced hospitalizations and deaths from COVID-19.
With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. Read on to see.
Protecting the most vulnerable, Eli Lilly’s bamlanivimab significantly reduced COVID-19 risk for nursing home residents in a Phase III trial.
The year is starting to pick up in terms of clinical trial announcements. Here’s a look at last week’s news.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers and Shakers.
JOBS
IN THE PRESS